Healthcare - Biotechnology - NASDAQ - US
$ 14.37
-0.76 %
$ 101 M
Market Cap
-0.6
P/E
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc.[ Read More ]
The intrinsic value of one CDTX stock under the base case scenario is HIDDEN Compared to the current market price of 14.4 USD, Cidara Therapeutics, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart CDTX
FINANCIALS
63.9 M
REVENUE
-24.5 M
OPERATING INCOME
-22.9 M
NET INCOME
-22.4 M
OPERATING CASH FLOW
-505 K
INVESTING CASH FLOW
26 M
FINANCING CASH FLOW
0
REVENUE
-17.4 M
OPERATING INCOME
-13 M
NET INCOME
-36.7 M
OPERATING CASH FLOW
-106 K
INVESTING CASH FLOW
-182 K
FINANCING CASH FLOW
Balance Sheet Decomposition
Cidara Therapeutics, Inc.
| Current Assets | 60.9 M |
| Cash & Short-Term Investments | 35.8 M |
| Receivables | 16.2 M |
| Other Current Assets | 8.83 M |
| Non-Current Assets | 6.18 M |
| Long-Term Investments | 0 |
| PP&E | 5.13 M |
| Other Non-Current Assets | 1.05 M |
| Current Liabilities | 67.4 M |
| Accounts Payable | 3.77 M |
| Short-Term Debt | 2.6 M |
| Other Current Liabilities | 61 M |
| Non-Current Liabilities | 7.82 M |
| Long-Term Debt | 3.58 M |
| Other Non-Current Liabilities | 4.24 M |
EFFICIENCY
Earnings Waterfall
Cidara Therapeutics, Inc.
| Revenue | 63.9 M |
| Cost Of Revenue | 1.52 M |
| Gross Profit | 62.4 M |
| Operating Expenses | 86.9 M |
| Operating Income | -24.5 M |
| Other Expenses | -1.55 M |
| Net Income | -22.9 M |
RATIOS
97.62%
GROSS MARGIN
-38.31%
OPERATING MARGIN
-35.88%
NET MARGIN
279.31%
ROE
-34.21%
ROA
361.29%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Cidara Therapeutics, Inc.
| Net Income | -22.9 M |
| Depreciation & Amortization | 118 K |
| Capital Expenditures | -505 K |
| Stock-Based Compensation | 3.06 M |
| Change in Working Capital | -3.92 M |
| Others | 4.94 M |
| Free Cash Flow | -22.9 M |
Wall Street Analysts Price Targets
Cidara Therapeutics, Inc.
Wall Street analysts predict an average 1-year price target for CDTX of $24 , with forecasts ranging from a low of $24 to a high of $24 .
CDTX Lowest Price Target
Wall Street Target
24 USD
67.01%
CDTX Average Price Target
Wall Street Target
24 USD
67.01%
CDTX Highest Price Target
Wall Street Target
24 USD
67.01%
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Cidara Therapeutics, Inc.
Sold
0-3 MONTHS
21.3 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
54.3 K USD 4
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
106 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
2 months ago
Sep 11, 2024
|
Sell 10.8 K USD
|
Sandison Taylor
Chief Medical Officer |
- 924
|
11.6367 USD |
|
2 months ago
Sep 11, 2024
|
Sell 10.6 K USD
|
Tari Leslie
CHIEF SCIENTIFIC OFFICER |
- 909
|
11.6393 USD |
|
5 months ago
Jun 07, 2024
|
Bought 106 K USD
|
Stein Jeffrey
President & CEO |
+ 8000
|
13.21 USD |
|
8 months ago
Mar 11, 2024
|
Sell 14.1 K USD
|
Tari Leslie
CHIEF SCIENTIFIC OFFICER |
- 21029
|
0.6698 USD |
|
8 months ago
Mar 11, 2024
|
Sell 13.8 K USD
|
Sandison Taylor
Chief Medical Officer |
- 20662
|
0.6698 USD |
|
8 months ago
Mar 11, 2024
|
Sell 13.7 K USD
|
Ward Shane
COO & CLO |
- 20473
|
0.6698 USD |
|
8 months ago
Mar 11, 2024
|
Sell 12.7 K USD
|
Shah Preetam
CFO & CBO |
- 18931
|
0.6698 USD |
|
1 year ago
Sep 11, 2023
|
Sell 17.5 K USD
|
Tari Leslie
CHIEF SCIENTIFIC OFFICER |
- 18469
|
0.948 USD |
|
1 year ago
Sep 11, 2023
|
Sell 17.8 K USD
|
Sandison Taylor
Chief Medical Officer |
- 18793
|
0.9477 USD |
|
1 year ago
Aug 14, 2023
|
Bought 9.7 K USD
|
Tari Leslie
CHIEF SCIENTIFIC OFFICER |
+ 10000
|
0.97 USD |
|
1 year ago
Aug 08, 2023
|
Bought 47.9 K USD
|
Stein Jeffrey
President & CEO |
+ 50000
|
0.9577 USD |
|
1 year ago
Mar 27, 2023
|
Bought 51.9 K USD
|
Stein Jeffrey
President & CEO |
+ 50000
|
1.0371 USD |
|
1 year ago
Mar 13, 2023
|
Sell 6.62 K USD
|
Ward Shane
COO & CLO |
- 4329
|
1.53 USD |
|
1 year ago
Mar 13, 2023
|
Sell 11.6 K USD
|
Tari Leslie
CHIEF SCIENTIFIC OFFICER |
- 7562
|
1.53 USD |
|
1 year ago
Mar 13, 2023
|
Sell 10.2 K USD
|
Shah Preetam
CFO & CBO |
- 6648
|
1.53 USD |
|
1 year ago
Mar 13, 2023
|
Sell 11 K USD
|
Sandison Taylor
Chief Medical Officer |
- 7203
|
1.53 USD |
|
1 year ago
Jan 12, 2023
|
Sell 14.2 K USD
|
Tari Leslie
CHIEF SCIENTIFIC OFFICER |
- 11814
|
1.2 USD |
|
2 years ago
Sep 19, 2022
|
Sell 12 K USD
|
Shah Preetam
CFO & CBO |
- 15642
|
0.7694 USD |
|
2 years ago
Sep 12, 2022
|
Sell 12.7 K USD
|
Sandison Taylor
Chief Medical Officer |
- 18478
|
0.6849 USD |
|
2 years ago
Sep 12, 2022
|
Sell 12.4 K USD
|
Tari Leslie
CHIEF SCIENTIFIC OFFICER |
- 18159
|
0.6849 USD |
|
2 years ago
Sep 12, 2022
|
Sell 11.1 K USD
|
Daruwala Paul
Chief Operating Officer |
- 16199
|
0.6849 USD |
|
2 years ago
Mar 21, 2022
|
Sell 530 USD
|
Johnson Brady
Vice President, Finance |
- 654
|
0.81 USD |
|
2 years ago
Mar 11, 2022
|
Sell 671 USD
|
Johnson Brady
Vice President, Finance |
- 945
|
0.71 USD |
|
2 years ago
Jan 05, 2022
|
Sell 6.42 K USD
|
Daruwala Paul
Chief Operating Officer |
- 5133
|
1.25 USD |
|
2 years ago
Jan 05, 2022
|
Sell 520 USD
|
Johnson Brady
Vice President, Finance |
- 416
|
1.25 USD |
|
2 years ago
Jan 05, 2022
|
Sell 1.56 K USD
|
Tari Leslie
Chief Scientific Officer |
- 1252
|
1.25 USD |
|
3 years ago
Nov 12, 2021
|
Bought 79.5 K USD
|
Stein Jeffrey
President & CEO |
+ 50000
|
1.5906 USD |
|
3 years ago
Nov 12, 2021
|
Bought 30.8 K USD
|
Shah Preetam
CFO & CBO |
+ 20000
|
1.54 USD |
|
3 years ago
Sep 13, 2021
|
Bought 14.8 K USD
|
Franson Timothy R
Director |
+ 7000
|
2.1175 USD |
|
3 years ago
Aug 19, 2021
|
Bought 17.9 K USD
|
Stein Jeffrey
President & CEO |
+ 10000
|
1.7871 USD |
|
3 years ago
Aug 18, 2021
|
Bought 68.9 K USD
|
Stein Jeffrey
President & CEO |
+ 40000
|
1.7221 USD |
|
3 years ago
Apr 01, 2021
|
Sell 3.91 K USD
|
Abdollahian Neil
Chief Business Officer |
- 1469
|
2.66 USD |
|
3 years ago
Jan 05, 2021
|
Sell 5.91 K USD
|
Abdollahian Neil
Chief Business Officer |
- 2868
|
2.06 USD |
|
3 years ago
Apr 01, 2021
|
Sell 1.58 K USD
|
Daruwala Paul
Chief Operating Officer |
- 593
|
2.66 USD |
|
3 years ago
Jan 05, 2021
|
Sell 5.91 K USD
|
Daruwala Paul
Chief Operating Officer |
- 2868
|
2.06 USD |
|
3 years ago
Apr 01, 2021
|
Sell 3.13 K USD
|
Oien Jessica
General Counsel & Secretary |
- 1177
|
2.66 USD |
|
3 years ago
Jan 05, 2021
|
Sell 1.7 K USD
|
Oien Jessica
General Counsel & Secretary |
- 824
|
2.06 USD |
|
4 years ago
Nov 10, 2020
|
Bought 100 K USD
|
Stein Jeffrey
President & CEO |
+ 50000
|
2.0003 USD |
|
4 years ago
Nov 10, 2020
|
Bought 101 K USD
|
Levine James E.
Chief Financial Officer |
+ 50000
|
2.0144 USD |
|
4 years ago
Jan 03, 2020
|
Sell 3.21 K USD
|
Abdollahian Neil
Chief Business Officer |
- 940
|
3.42 USD |
|
4 years ago
Jan 03, 2020
|
Sell 3.21 K USD
|
Daruwala Paul
Chief Operating Officer |
- 940
|
3.42 USD |
|
5 years ago
Sep 24, 2019
|
Bought 57.2 K USD
|
Levine James E.
Chief Financial Officer |
+ 30000
|
1.908 USD |
|
4 years ago
Jan 02, 2020
|
Sell 3.22 K USD
|
Oien Jessica
General Counsel & Secretary |
- 834
|
3.86 USD |
|
4 years ago
Jan 03, 2020
|
Sell 8 K USD
|
Abdollahian Neil
Chief Business Officer |
- 2340
|
3.42 USD |
|
4 years ago
Jan 03, 2020
|
Sell 8 K USD
|
Daruwala Paul
Chief Operating Officer |
- 2340
|
3.42 USD |
|
5 years ago
Oct 02, 2019
|
Sell 6.19 K USD
|
Daruwala Paul
Chief Operating Officer |
- 3295
|
1.88 USD |
|
5 years ago
Oct 01, 2019
|
Sell 14.4 K USD
|
Abdollahian Neil
Chief Business Officer |
- 7284
|
1.98 USD |
|
5 years ago
Sep 27, 2019
|
Sell 1.86 K USD
|
Oien Jessica
General Counsel & Secretary |
- 1001
|
1.86 USD |
|
5 years ago
Sep 24, 2019
|
Bought 100 K USD
|
Stein Jeffrey
President & CEO |
+ 52500
|
1.9067 USD |
|
5 years ago
Sep 24, 2019
|
Bought 57.2 K USD
|
Levine James E.
Chief Financial Officer |
+ 30000
|
1.908 USD |
|
5 years ago
Mar 08, 2019
|
Sell 5.61 K USD
|
Abdollahian Neil
Chief Business Officer |
- 2300
|
2.44 USD |
|
5 years ago
Mar 07, 2019
|
Sell 5.71 K USD
|
Daruwala Paul
Chief Operating Officer |
- 2240
|
2.5507 USD |
|
6 years ago
May 23, 2018
|
Bought 1 M USD
|
Stein Jeffrey
President & CEO |
+ 212766
|
4.7 USD |
|
7 years ago
Nov 15, 2017
|
Bought 454 K USD
|
BIOTECH TARGET N V
10 percent owner |
+ 60000
|
7.5661 USD |
|
7 years ago
Sep 12, 2017
|
Bought 49.9 K USD
|
Stein Jeffrey
President & CEO |
+ 7350
|
6.79 USD |
|
7 years ago
Jun 07, 2017
|
Bought 114 K USD
|
Sandison Taylor
Chief Medical Officer |
+ 19344
|
5.9 USD |
|
7 years ago
Jun 06, 2017
|
Bought 3.87 K USD
|
Sandison Taylor
Chief Medical Officer |
+ 656
|
5.9 USD |
|
7 years ago
Jun 05, 2017
|
Bought 89.2 K USD
|
Stein Jeffrey
President & CEO |
+ 15000
|
5.9474 USD |
|
7 years ago
Mar 31, 2017
|
Bought 96.9 K USD
|
Forrest Kevin
Chief Scientific Officer |
+ 12500
|
7.75 USD |
|
7 years ago
Mar 31, 2017
|
Bought 100 K USD
|
Stein Jeffrey
President & CEO |
+ 12900
|
7.75 USD |
|
8 years ago
May 20, 2016
|
Bought 50.2 K USD
|
Forrest Kevin
COO & CFO |
+ 4356
|
11.53 USD |
|
8 years ago
May 20, 2016
|
Bought 49.6 K USD
|
Stein Jeffrey
President & CEO |
+ 4310
|
11.51 USD |
|
8 years ago
Nov 25, 2015
|
Bought 20.3 K USD
|
Stein Jeffrey
President & CEO |
+ 1300
|
15.6 USD |
|
8 years ago
Nov 24, 2015
|
Bought 80.8 K USD
|
Stein Jeffrey
President & CEO |
+ 5400
|
14.97 USD |
|
8 years ago
Nov 23, 2015
|
Bought 101 K USD
|
Forrest Kevin
COO & CFO |
+ 7087
|
14.23 USD |
|
9 years ago
Apr 20, 2015
|
Bought 2.49 M USD
|
Heron Patrick J
Director |
+ 155645
|
16 USD |
|
9 years ago
Apr 20, 2015
|
Bought 2.49 M USD
|
Heron Patrick J
Director |
+ 155645
|
16 USD |
|
9 years ago
Apr 20, 2015
|
Bought 710 K USD
|
Heron Patrick J
Director |
+ 44355
|
16 USD |
|
9 years ago
Apr 20, 2015
|
Bought 710 K USD
|
Heron Patrick J
Director |
+ 44355
|
16 USD |
|
9 years ago
Apr 20, 2015
|
Bought 3.2 M USD
|
Kjellson Nina S
Director |
+ 200000
|
16 USD |
|
9 years ago
Apr 20, 2015
|
Bought 6.72 K USD
|
Stein Jeffrey
President & CEO |
+ 420
|
16 USD |
|
9 years ago
Apr 20, 2015
|
Bought 80 K USD
|
PEREZ ROBERT J
Director |
+ 5000
|
16 USD |
|
9 years ago
Apr 20, 2015
|
Bought 64 K USD
|
Franson Timothy R
Director |
+ 4000
|
16 USD |
|
9 years ago
Apr 20, 2015
|
Bought 48 K USD
|
BURGESS DANIEL D
Director |
+ 3000
|
16 USD |
7. News
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the third quarter ended September 30, 2024, and provided an update on its corporate activities and product pipeline.
globenewswire.com
- 1 week ago
Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the following November investor conferences.
globenewswire.com
- 2 weeks ago
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the Compensation Committee of its Board of Directors (Compensation Committee) granted Dipesh Bhatt, a new employee, a non-qualified stock option award and restricted stock units (RSUs) for an aggregate of 1,110 shares of its common stock, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, as amended (the Inducement Plan), with a grant date of September 30, 2024. The stock option has an exercise price of $10.75 per share, which is equal to the closing price of Cidara's common stock on the grant date. The shares subject to the option will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. All RSUs vest in four equal annual installments, with 1/4 vesting on each of the first, second, third and fourth anniversaries of the Quarterly Vesting Date (as defined below) that occurs during the calendar quarter that includes the date of grant. “Quarterly Vesting Date” means March 10, June 10, September 10 or December 10. The awards are subject to the award holder's continuous service through each vesting date and to the terms and conditions of the Inducement Plan and the standard forms of grant agreements thereunder.
globenewswire.com
- 1 month ago
Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference
SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced two presentations at OPTIONS XII for the Control of Influenza conference, to be held September 29 through October 2, 2024 in Brisbane, Australia. The presentations, one oral and one poster, will highlight safety and pharmacokinetic (PK) data from clinical studies of CD388, Cidara's influenza drug-Fc conjugate (DFC) candidate.
globenewswire.com
- 1 month ago
Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza
The Phase 2b trial will enroll 5,000 subjects across clinical sites in the US and UK The Phase 2b trial will enroll 5,000 subjects across clinical sites in the US and UK
globenewswire.com
- 1 month ago
Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts
SAN DIEGO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the appointment of Rick Bright, Ph.D., Philip Krause, M.D., Mario Barro, Ph.D., and Frederick G. Hayden, M.D., FACP to its Scientific Advisory Board (SAB).
globenewswire.com
- 1 month ago
Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced a reduction in its workforce to focus on the clinical development of CD388, the Company's novel DFC candidate for influenza A and B. The planned reduction impacts approximately 30% of the Cidara workforce.
globenewswire.com
- 2 months ago
Cidara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference.
globenewswire.com
- 2 months ago
Cidara Therapeutics Announces Appointment of Jim Beitel as Chief Business Officer
Appointment adds biotech veteran with over two decades of business development, strategy, and operational experience to Cidara's management team Appointment adds biotech veteran with over two decades of business development, strategy, and operational experience to Cidara's management team
globenewswire.com
- 2 months ago
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the second quarter ended June 30, 2024, and provided an update on its corporate activities and product pipeline.
globenewswire.com
- 3 months ago
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the Compensation Committee of its Board of Directors granted Corrina Pavetto, a new employee, a non-qualified stock option award and restricted stock units (RSUs) for an aggregate of 10,275 shares of its common stock, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, with a grant date of June 28, 2024. The stock option has an exercise price of $11.94 per share, which is equal to the closing price of Cidara's common stock on the grant date. The shares subject to the option will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. All RSUs vest in four equal annual installments, with 1/4 vesting on each of the first, second, third and fourth anniversaries of the Quarterly Vesting Date that occurs during the calendar quarter that includes the Date of Grant. Quarterly Vesting Date means March 10, June 10, September 10 or December 10. The awards are subject to the award holder's continuous service through each vesting date and to the terms and conditions of Cidara's 2020 Inducement Incentive Plan and its standard forms of grant agreements thereunder.
globenewswire.com
- 4 months ago
Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company will be presenting a poster at the American Society for Microbiology (ASM) Microbe 2024 conference to be held June 13-17, 2024 at the Georgia World Congress Center in Atlanta, Georgia.
globenewswire.com
- 5 months ago
8. Profile Summary
Cidara Therapeutics, Inc. CDTX
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 101 M
Dividend Yield
0.00%
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Contact
6310 Nancy Ridge Drive, San Diego, CA, 92121
https://www.cidara.com
IPO Date
April 15, 2015
Employees
69
Officers
Mr. Jim Beitel M.B.A.
Chief Business Officer
Dr. Kevin M. Forrest Ph.D.
Founder & Chief Strategy Officer
Dr. Preetam Shah M.B.A., Ph.D.
Chief Financial Officer & Principal Accounting Officer
Ms. Allison Lewis CCP, SPHR
Senior Vice President of People & Culture
Dr. Leslie Tari Ph.D.
Chief Scientific Officer
Mr. Shane M. Ward
Chief Operating Officer & Corporate Secretary
Dr. Jeffrey L. Stein Ph.D.
President, Chief Executive Officer & Executive Director
Dr. Taylor Sandison M.D., M.P.H.
Chief Medical Officer
Dr. Nicole Davarpanah J.D., M.D.
Senior Vice President of Translational Research & Development